Important Intravenous Nutrients for Cancer Patients

More than 90 percent of cancer patients who die do so because of metastasis. When chemotherapy, surgery, and radiation fail, as they commonly do in late stage cancers, metastasis grow exponentially. 'Metastasis' is the spread of cancer. What many people do not know is that metastasis begins on the cellular level, in the very early stages of the cancer. This is called micro-metastasis. When micro-metastases begin to invade tissue at a macro level, metastatic cancer then occurs.

Many cancer patients have micro-metastasis occurring, yet their oncologists can never really be too sure of what's happening because they are often undetectable. Many patients are told that the only way to really know if they have received an effective outcome with conventional treatment is to watch and wait and to "allow time to be the best determining factor for a successful treatment" – a statement that has virtually become a "popular oncology" mantra.

To further complicate matters, it has been shown that some metastases are active while other forms are more dormant in an arrested cell cycle waiting for messengers to start them up again.

There are also forms of metastasis that go untouched or unaffected by chemotherapy as they do not behave as "normal" cancer cells do. The problem with current conventional cancer treatment could not be more clear: The World is in dire need of a more effective way to combat metastasis. This is the very notion that inspired the founder of Envita to create such a truly integrative cancer center.

Clinical Practices Must Lead the way, Not the Pharmaceutical Companies

In 2006, we discovered a common problem among advanced Cancer patients was significantly impaired immunity. Specifically, cells of the immune system called CD56 and CD57 Natural Killer cells, were greatly depleted. It appeared that the patient's prognosis would be inextricably tied to the presence of these cells or the respective lack thereof and their ability to destroy metastasis.

Armed with knowledge from years of research, we began to develop a customized natural killer cell vaccine. What makes this treatment so special is that it is greatly enhancing the body's own "intelligent" natural mechanism to combat metastasis. The immune system has the ability to "think" unlike any drug or radiation device. Why? Because Natural Killer Cells have only two significant functions – find and destroy cancer cells (as well as dormant metastatic cells) and viruses. Helping patients overcome metastasis became our main goal.

AAIT: Autologous Adoptive Immune Therapy Cancer Treatment

AAIT can help the body's own immune system to kill off cancer cells and attack metastasis in a completely different manner than chemotherapy, radiotherapy, or even surgery. AAIT is only available at Envita Mexico and is not approved by the FDA for the treatment of cancer. AAIT is much like an immune system transplant. However, unlike organ transplants where organs are obtained from one person and given to another, the cells that are transplanted in the AAIT process are actually autologous (taken from the patients' own cells.) In fact, AAIT cells are harvested from the patient, grown in the lab into therapeutic numbers, activated, trained to seek out and destroy cancer cells, tumors, and most of all, metastatic cancer cells, before it is reintroduced into the patient's body. AAIT also removes important factors that have been known to block or impede immunity in cancer patients.

Not the First Immunotherapy for Cancer, However it is the Most "Intelligent"

We immediately found that the patients receiving AAIT were living longer with a tremendous improvement in quality of life. Even those combating complex late stage cancers were excited about the possibility of remission.

It should be said that about 14 years earlier, a company called Dendron, had built a dendritic cell cancer vaccine call Provenge. The dendritic cell type, however, merely passes information on to the natural killer cell – they are not actually killers themselves. Nevertheless, Provenge was a piece to the immune system puzzle that particularly dealt with metastasis.

The next great breakthrough was the recognition that natural killer cells worked as a vaccine. Our unique approach to cancer treatment allows patients to overcome cancer, including complex cancers that had become virtually untreatable by conventional standards.

Major Upgrade with the Discovery of Natural Killer Cell Blockers and Enhancers

We discovered that organizations such as Mayo Clinic, Stanford University, and others had been working on their own versions of natural killer cell treatments and vaccines. From thorough research, we found that our own AAIT protocol had well over two times the tumor kill as the competition, with billions more cells delivered to the body and maximizing therapeutic dosages than any previous institution has yet to report.

If these Natural Killer cells are soldiers specifically equipped to fight cancer, two important criteria must be considered when building a vaccine:

  • Are there an adequate number of soldiers being recruited for the fight?
  • How well trained are the soldiers being sent to battle the cancer?

Our protocol outperforms every treatment that has come before it, which truly is a breakthrough.

Deeper Discovery Giving Way to the Future of Immunotherapy

We began to notice that some patients reacted extremely well while others saw more subtle improvements in comparison but still with a greatly improved quality of life. Some patients, however, didn't respond quite as well as they had hoped.

The medical team found that cancer cells evolve and develope several natural killer cell blockers in order to ensure it's survival in the body and to resist the body's natural killing mechanism. This was especially true in patients that had previously been treated with radiation and/or chemotherapy treatment. As a result of treatment, the tumors and cancer cells would adapt and protect themselves in order to survive.

What the team found was a way to remove the blocker mechanisms and to make the natural killer cell vaccine many times more effective for patients by ensuring the treatment would be well received by the body. With extreme customization for each person's individual immune system, the vaccine could be developed to be optimized to suit the patient's specific, personal needs while addressing the specific make up and mutations of their specific cancer.

Pioneers; The Politics involved in the Development of a New Cancer Treatment

It would be nice to think that all cancer treatments are based simply on good science, great patient care, and life-saving innovations. In reality, that's not necessarily always the case. The FDA issued a warning letter to Envita for not registering the biologics product as a new research drug with IND application.

In 2008, we were finally granted permission by the FDA and IND to pursue a phase one drug study using the body's own immune system to fight cancer. An amazing and daunting task to accomplish in just 2 short years became possible due to the fact that the data was strong and well documented. Since we are primarily an integrative medical center, the team did not want to limit their biologics development or the opportunity to use its natural killer cell vaccine to help patients. As a result, we partnered with oncologist and bone marrow specialist Joel Badell MD and Professor Antonio Rascon, head of the hematology oncology division for CIMA Hospital in Hermosillo, Mexico, which is also one of Mexico's top-most respected hospital systems in the country.

Our highest priority has always been to continually develop new generations of therapeutics created from the body's own cell types which are naturally occurring and vital to fighting cancer including metastasis. Within a few short years, we have proven that it is possible to produce customized vaccines and make significant difference in helping patients fight cancer.

Today, Envita continues to employ biologics engineering, techniques, and sophisticated technologies to develop medicines that address significant, specific, and previously unmet needs in order to provide clinical benefits to patients worldwide. With exciting breakthroughs on numerous cancer types, AAIT has a very bright future as, "The world's most intelligent cancer treatment." Our AAIT is developed today to cover, breast, prostate, pancreatic, lung, colon, various leukemia's, Brain, Kidney, esophageal, ovarian, uterine, lymphomas including other later stage cancers.

Watch more in-depth video on the science of AAIT. Contact us today and let us know how we can help.

This treatment not available in US and it is not FDA approved for the treatment of cancer. Patients should consult with their doctors before considering any therapy or treatment. Envita Mexico is governed under Mexican law and medical legal jurisdiction, and in no way do we make any guarantees or claims of any outcomes for this or any other treatment. The information above is for educational purposes only.

Get in contact with us!

Welcome to Envita's Biologics Division! Our AAIT method is the latest in our line of cancer and immunotherapy treatments and in comparison to immunotherapy options that are currently available in United States as well as abroad, it boasts a significant level of tumor kill without having to resort to biopsy. AAIT can be used in addition to chemotherapy, radiotherapy and/or delivered intra-operatively. It's very important to note that AAIT can also be utilized completely independent of chemotherapy and radiation because it leverages a completely different mechanism of tumor kill. If you have any questions or would like to speak to our clinicians directly, please send us an email. To learn more about how you or your institution can become part of our Envita Mexico team, please don't hesitate to contact us.

Toll Free: 1.866.830.4576
Phone: 602.569.4144

Your message has been sent!